Avita Medical reports Q4 EPS (38c), consensus (55c)

Reports Q4 revenue $17.62M, consensus $25.23M. Cary Vance, interim CEO of Avita Medical (RCEL), commented: “The fourth quarter marked the close of a year of stabilization, and the beginning of a more execution-focused phase, for the Company. While reimbursement disruption and operational transition weighed on revenue performance in 2025, those issues are now largely behind us, and we are seeing early signs of normalization in clinician use of RECELL. We enter 2026 with a clearer commercial focus and a validated portfolio that supports growth through deeper utilization within our core burn and trauma centers, with our priority centered on delivering consistent, execution-led growth quarter by quarter.”